M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 3.97 USD -1.98% Market Closed
Market Cap: 244.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 16.49 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

GLUE Lowest Forecast
Wall Street Target
10.1 USD
154% Upside
GLUE Average Forecast
Wall Street Target
16.49 USD
315% Upside
GLUE Highest Forecast
Wall Street Target
21 USD
429% Upside
Lowest
Price Target
10.1 USD
154% Upside
Average
Price Target
16.49 USD
315% Upside
Highest
Price Target
21 USD
429% Upside
Monte Rosa Therapeutics Inc Competitors:
Price Targets
AMGN
Amgen Inc
18% Upside
GNS
Genus PLC
22% Upside
E
206650
EuBiologics Co Ltd
25% Upside
ADAG
Adagene Inc
466% Upside
AMGN
Amgen Inc
18% Upside
GNS
Genus PLC
22% Upside
E
206650
EuBiologics Co Ltd
25% Upside
ADAG
Adagene Inc
466% Upside
LEGN
Legend Biotech Corp
171% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
20% Upside

Revenue
Forecast

Revenue Estimate
Monte Rosa Therapeutics Inc

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 3 years is -1%.

N/A
Past Growth
-1%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Monte Rosa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Monte Rosa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
What are analyst estimates?

See Also

Summary
GLUE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLUE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLUE stock valuation using valuation multiples.
Wall Street Estimates
GLUE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLUE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLUE's stock price target?
Price Target
16.49 USD

According to Wall Street analysts, the average 1-year price target for GLUE is 16.49 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

What is Monte Rosa Therapeutics Inc's Revenue forecast?
Projected CAGR
-1%

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 3 years is -1%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.